Lantern Grants

Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)

Funder
National Institutes of Health
Award amount
Not specified
Deadline
January 25, 2027
Eligible countries
United States

Summary

Forecasted opportunity (not yet open for applications; expected to be posted around 2026-11-25; estimated application due date 2027-01-25). The goal of this RFA is to continue to support canine cancer immunotherapy clinical trials as indicators of safe and effective cancer treatments in humans. Pet dog patients develop cancer spontaneously and the courses of disease and treatment responses are similar to those in humans. Canine clinical trial results are translatable to humans. The assessment of responses to immunotherapy in immune-intact animals with existing cancers, such as pet dog patients, is the only way to preclinically take into account all facets of the immune response to cancer and to therapies. Ethically, pet dogs can benefit from the clinical trials by receiving cutting-edge therapies supported by the NIH, while providing important data informative to human disease. The network supported by this U01 RFA will consist of five U01 awards. One U01 will serve as a multifunctional Network Coordinating Center that will not only facilitate coordination across the Canine Cancer Immunotherapy Network (K9CIN) but will also perform limited research to support the network. Four U01 recipients will conduct canine clinical trials using immunotherapeutic agents alone or in combination with other treatment modalities.Through this reissue Notice of Funding Opportunity, the National Cancer Institute intends to continue to support canine immunotherapeutic development as the field continues to grow, in part because of NIH funding. In the last five years, canine immunotherapeutics such as immune checkpoint inhibitors have become available as have canine analytics, development of which were partially supported by NCI. The goal is to maintain the momentum for further development of canine analytics and therapeutics and the ability to evaluate novel and repurposed drugs, treatment combinations, and treatment dosing and sequencing in pet dogs in a timely fashion. This NOFO…

Summary as listed on Grants.gov (opportunity 361532). Always read the full announcement for eligibility, limits and how to apply.

Read the full announcement on Grants.gov →

This is an NIH U01 call. Read our plain-language guide to the mechanism: who is eligible, typical budgets and how applications are reviewed.

What National Institutes of Health reviewers look for

  • Importance of the research (significance and innovation), scored 1–9.
  • Rigor and feasibility of the approach, scored 1–9. Preliminary data and alternative strategies carry much of this.
  • Expertise and resources, rated sufficient or not, without a score.
  • Overall impact: the likelihood the project will have a sustained, powerful influence on its field.

Read our guide: what funded applications do →

See how this call matches your research

Build a free research profile and Lantern Grants scores every open call against your work, tracks your deadlines and reminds you before they pass.

Get matched free